PLAAT2 suppresses gastric cancer progression by facilitating cMyc ubiquitination and inhibiting MEK/ERK signaling - PubMed
5 hours ago
- #Gastric Cancer
- #PLAAT2
- #Ubiquitination
- PLAAT2 suppresses gastric cancer (GC) progression by facilitating cMyc ubiquitination and inhibiting MEK/ERK signaling.
- PLAAT2 is downregulated in GC and correlates with poor prognosis.
- Functional experiments show PLAAT2 inhibits GC cell proliferation, migration, and invasion via the MEK/ERK pathway.
- IP-MS and co-IP reveal cMyc and TRIM32 as key PLAAT2-binding partners.
- PLAAT2 recruits TRIM32 to promote cMyc ubiquitination and degradation, suppressing oncogenic signaling.
- In vivo xenograft models validate PLAAT2's tumor-suppressive role.
- The PLAAT2/TRIM32/cMyc axis is highlighted as a potential therapeutic target.